Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study - PubMed (original) (raw)

. 2012 Jul;35(7):1538-43.

doi: 10.2337/dc11-1513. Epub 2012 May 22.

Affiliations

Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study

Rachel Dankner et al. Diabetes Care. 2012 Jul.

Abstract

Objective: Diabetes is associated with many forms of cancer. Recent evidence has suggested that some treatments for diabetes are associated with an increased cancer risk. Less is known about the association between endogenous insulin in the prediabetes state and cancer risk.

Research design and methods: We investigated cumulative cancer incidence and cancer incidence density over 29 years, according to basal insulin, in a cohort of 1,695 nondiabetic men and women of four ethnic origins, aged 51.8 ± 8.0 years at baseline. Total mortality among the 317 subjects (18.7%) who developed cancer at least 2 years after baseline was assessed.

Results: In a Cox proportional hazards model, the all-site hazard ratio of cancer incidence comparing the highest insulin quartile with the other three quartiles was 1.09 (95% CI 0.85-1.40), adjusted for age, sex, and ethnicity. BMI, smoking, and fasting blood glucose were not statistically significant in this model. Basal insulin level was not significantly associated with cancer of specific sites (breast, prostate, colon/rectum, or bladder). Fasting insulin in the upper quartile conferred a 37% increased risk for total mortality among cancer patients, adjusting for age, sex, and ethnic origin (95% CI 0.94-2.00, P = 0.097) compared with that of the lower quartiles. Male sex, older age, and North African origins were associated with a greater risk of mortality during follow-up time.

Conclusions: This long-term cohort study may suggest a role for basal elevated insulin levels, mainly as a negative predictor in cancer prognosis.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Age-adjusted cumulative survival among cancer incident patients by basal insulin. The curves represent the cumulative survival of cancer incident patients over 18 years of follow-up according to baseline basal insulin in the lower three quartiles (Q1-Q3) and the upper quartile (Q4).

References

    1. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674–1685 - PMC - PubMed
    1. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076–2083 - PMC - PubMed
    1. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007;121:856–862 - PubMed
    1. Zhou XH, Qiao Q, Zethelius B, et al. DECODE Study Group Diabetes, prediabetes and cancer mortality. Diabetologia 2010;53:1867–1876 - PubMed
    1. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819–2823 - PubMed

MeSH terms

Substances

LinkOut - more resources